Wells Fargo & Company Lumos Pharma, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding LUMO
# of Institutions
41Shares Held
2.19MCall Options Held
0Put Options Held
0-
Goldman Sachs Group Inc New York, NY407KShares$1.55 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$927,5110.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny216KShares$820,0930.0% of portfolio
-
Acuitas Investments, LLC141KShares$537,4530.19% of portfolio
-
Jefferies Group LLC New York, NY121KShares$458,4730.01% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $31.9M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...